Consun Pharmaceutical Group Limited (1681.HK)
- Previous Close
5.720 - Open
5.720 - Bid 5.680 x --
- Ask 5.700 x --
- Day's Range
5.590 - 5.720 - 52 Week Range
4.310 - 5.990 - Volume
917,800 - Avg. Volume
739,765 - Market Cap (intraday)
4.618B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
5.38 - EPS (TTM)
1.060 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield 0.45 (7.87%)
- Ex-Dividend Date Jun 11, 2024
- 1y Target Est
9.69
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
www.chinaconsun.com3,127
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 1681.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1681.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1681.HK
Valuation Measures
Market Cap
4.63B
Enterprise Value
1.31B
Trailing P/E
5.40
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.63
Price/Book (mrq)
1.18
Enterprise Value/Revenue
0.51
Enterprise Value/EBITDA
1.48
Financial Highlights
Profitability and Income Statement
Profit Margin
30.29%
Return on Assets (ttm)
9.93%
Return on Equity (ttm)
21.38%
Revenue (ttm)
2.59B
Net Income Avi to Common (ttm)
784.53M
Diluted EPS (ttm)
1.060
Balance Sheet and Cash Flow
Total Cash (mrq)
3.58B
Total Debt/Equity (mrq)
13.05%
Levered Free Cash Flow (ttm)
--
Research Analysis: 1681.HK
Company Insights: 1681.HK
1681.HK does not have Company Insights